Technical Analysis for CALT - Calliditas Therapeutics AB
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Fell Below 20 DMA | Bearish | -2.22% | |
Fell Below 50 DMA | Bearish | -2.22% | |
MACD Bearish Centerline Cross | Bearish | -2.22% | |
Inside Day | Range Contraction | -2.22% | |
Crossed Above 20 DMA | Bullish | -3.84% | |
Crossed Above 50 DMA | Bullish | -3.84% | |
MACD Bullish Centerline Cross | Bullish | -3.84% | |
Gapped Down | Weakness | -3.84% |
Alert | Time |
---|---|
Possible NR7 | about 5 hours ago |
Fell Below Previous Day's Low | about 8 hours ago |
Down 2 % | about 8 hours ago |
Down 1% | about 8 hours ago |
10 DMA Resistance | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Calliditas Therapeutics AB Description
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Pharmacy Medication Pharmaceutical Products Kidney Disease Renal Disease Pharmaceutics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 29.3 |
52 Week Low | 15.25 |
Average Volume | 8,126 |
200-Day Moving Average | 19.26 |
50-Day Moving Average | 21.73 |
20-Day Moving Average | 21.81 |
10-Day Moving Average | 21.59 |
Average True Range | 0.85 |
RSI (14) | 44.75 |
ADX | 11.36 |
+DI | 23.31 |
-DI | 25.34 |
Chandelier Exit (Long, 3 ATRs) | 20.80 |
Chandelier Exit (Short, 3 ATRs) | 22.86 |
Upper Bollinger Bands | 23.17 |
Lower Bollinger Band | 20.45 |
Percent B (%b) | 0.21 |
BandWidth | 12.49 |
MACD Line | -0.08 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.0763 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 21.01 | ||||
Resistance 3 (R3) | 21.01 | 21.01 | 21.01 | ||
Resistance 2 (R2) | 21.01 | 21.01 | 21.01 | 21.01 | |
Resistance 1 (R1) | 21.01 | 21.01 | 21.01 | 21.01 | 21.01 |
Pivot Point | 21.01 | 21.01 | 21.01 | 21.01 | 21.01 |
Support 1 (S1) | 21.01 | 21.01 | 21.01 | 21.01 | 21.01 |
Support 2 (S2) | 21.01 | 21.01 | 21.01 | 21.01 | |
Support 3 (S3) | 21.01 | 21.01 | 21.01 | ||
Support 4 (S4) | 21.01 |